[Conjugates of 2',3'-didehydro-3'-deoxythymidine with thymogen. Synthesis and anti-HIV activity].
Riakhovskiĭ. V V VV; Malekin. S I SI; Nosova. V M VM; Kisin. A V AV; Krugliak. Iu L IuL; Kurochkin. V K VK
Key Findings
- A thymogen‑d4T conjugate was successfully synthesized.
- The d4T‑tryptophan conjugate kept anti‑HIV activity comparable to d4T alone.
- The conjugate showed no detectable cytotoxicity in vitro.
Practical Outcomes
- The main takeaway is that attaching d4T to thymogen via tryptophan may create a less toxic anti‑HIV compound. This is interesting for HIV treatment research but offers no immediate, actionable protocol for general health or performance optimization.
Summary
Scientists made a new version of the anti‑HIV drug d4T by attaching it to a small peptide called thymogen. The version linked through tryptophan worked just as well against HIV as the original drug but didn’t show any cell toxicity in lab tests. While this shows a safer way to deliver the drug, it doesn’t give any direct tips for everyday health, longevity, or performance improvements for most people.
Abstract
An effective synthesis of thymogen was developed. Conjugates of 2',3'-didehydro-3'-deoxythymidine (nucleoside d4T) with thymogen were prepared in which the nucleoside hydroxyl group was linked to the thymogen carboxyl group of either tryprophan or glutamic acid residues. It was shown that the anti-HIV activity of the d4T-thymogene conjugate with the tryptophan linkage was comparable to that of d4T, whereas its cytotoxicity was nil. The d4T-tryptophan conjugate also displayed high anti-HIV activity.
Study Information
pubmed
1999